The miR-200 family in ovarian cancer

Maria Koutsaki; Massimo Libra; Demetrios A. Spandidos; Apostolos Zaravinos

doi:10.18632/oncotarget.18343

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The miR-200 family in ovarian cancer

Maria Koutsaki, Massimo Libra, Demetrios A. Spandidos and Apostolos Zaravinos _

PDF | HTML | How to cite

Oncotarget. 2017; 8:66629-66640. https://doi.org/10.18632/oncotarget.18343

Metrics: PDF 2658 views | HTML 3688 views | ?

Abstract

Maria Koutsaki1, Massimo Libra2, Demetrios A. Spandidos3 and Apostolos Zaravinos4

13rd Department of Pediatrics of the National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece

2Department of Biomedical and Biotechnological Sciences, Laboratory of Translational Oncology and Functional Genomics, Section of General and Clinical Pathology and Oncology, University of Catania, 95124 Catania, Italy

3Laboratory of Virology, Medical School, University of Crete, 71110 Heraklion, Crete, Greece

4Department of Life Sciences, School of Sciences, European University Cyprus, 1516 Nicosia, Cyprus

Correspondence to:

Apostolos Zaravinos, email: [email protected]

Keywords: miR-200 family, ovarian cancer, prognosis, disease stage, tumor histology

Received: December 06, 2016 Accepted: May 22, 2017 Published: June 02, 2017

ABSTRACT

Ovarian cancer (OC) is the most lethal gynecological malignancy. Its insidious nature, manifesting with little to no symptoms until the disease progresses to metastasis, along with a wide diversity of histological subtypes and corresponding clinical behavior, poses significant therapeutic challenges. The genetic profiling of this aggressive tumor and its subtypes has led to the identification of various molecular markers of prognosis. Among these, the miR-200 family of miRNAs appears to play an important role. The deregulated expression of the miR-200 family members has been detected in a variety of OC studies. The present review examines the potential usefulness of the miR-200 family members as prognostic indicators in ovarian cancer and their impact across different OC publications, with a particular focus on prognostic features, such as disease stage, tumor histology, survival and response to chemotherapy. We present the potential usefulness of the miR-200 family genes as prognostic indicators in OC and highlight the tendency that miR-200 overexpression corresponds with an advanced cancer stage.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18343

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

The miR-200 family in ovarian cancer

Abstract